Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression

Caroline C. van der Hoogt,[1],[*],[†] Willeke de Haan,[1],[*],[†] Marit Westerterp,[*],[†] Menno Hoekstra,[§] Geesje M. Dallinga-Thie,[**] Johannes A. Romijn,[†] Hans M. G. Princen,[*] J. Wouter Jukema,[††] Louis M. Havekes,[*],[†],[††] and Patrick C. N. Rensen[2],[*],[†]

Netherlands Organization for Applied Scientific Research-Quality of Life,[*] Gaubius Laboratory, 2301 CE Leiden, The Netherlands; Departments of General Internal Medicine, Endocrinology, and Metabolic Diseases,[†] and Cardiology,[††] Leiden University Medical Center, 2300 RC Leiden, The Netherlands; Leiden/Amsterdam Center for Drug Research,[§] Division of Biopharmaceutics, 2300 RA Leiden, The Netherlands; and Department of Internal Medicine,[**] Erasmus University Rotterdam, 3000 DR Rotterdam, The Netherlands

Abstract In addition to efficiently decreasing VLDL-triglycerides (TGs), fenofibrate increases HDL-cholesterol levels in humans. We investigated whether the fenofibrate-induced increase in HDL-cholesterol is dependent on the expression of the cholesteryl ester transfer protein (CETP). To this end, APOE*3-Leiden (E3L) transgenic mice without and with the human CETP transgene, under the control of its natural regulatory flanking regions, were fed a Western-type diet with or without fenofibrate. Fenofibrate (0.04% in the diet) decreased plasma TG in E3L and E3L.CETP mice (-59% and -60%; $P < 0.001$), caused by a strong reduction in VLDL. Whereas fenofibrate did not affect HDL-cholesterol in E3L mice, fenofibrate dose-dependently increased HDL-cholesterol in E3L.CETP mice (up to $+91\%$). Fenofibrate did not affect the turnover of HDL-cholesteryl ester (CE), indicating that fenofibrate causes a higher steady-state HDL-cholesterol level without altering the HDL-cholesterol flux through plasma. Analysis of the hepatic gene expression profile showed that fenofibrate did not differentially affect the main players in HDL metabolism in E3L.CETP mice compared with E3L mice. However, in E3L.CETP mice, fenofibrate reduced hepatic CETP mRNA (-72%; $P < 0.01$) as well as the CE transfer activity in plasma (-73%; $P < 0.01$).⬛ We conclude that fenofibrate increases HDL-cholesterol by reducing the CETP-dependent transfer of cholesterol from HDL to (V)LDL, as related to lower hepatic CETP expression and a reduced plasma (V)LDL pool.—van der Hoogt, C. C., W. de Haan, M. Westerterp, M. Hoekstra, G. M. Dallinga-Thie, J. A. Romijn, H. M. G. Princen, J. W. Jukema, L. M. Havekes, and P. C. N. Rensen. **Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression.** *J. Lipid Res.* 2007. **48:** 1763–1771.

Supplementary key words fibrate • high density lipoprotein • peroxisome proliferator-activated receptor α • transgenic mice

High plasma triglyceride (TG) levels are correlated with an increased risk for cardiovascular disease (1). Fibrates are widely used to reduce hypertriglyceridemia, thereby generating a less atherogenic lipid phenotype. Fibrates perform their actions through the activation of peroxisome proliferator-activated receptor α (PPARα) (2, 3). Activated PPARα heterodimerizes with retinoid X receptor and subsequently binds to specific peroxisome proliferator response elements (PPREs) in target genes to alter their transcription (2, 4). Fibrates thus decrease TG levels by inhibiting hepatic TG production through increased hepatic β-oxidation and inhibition of de novo fatty acid synthesis, increasing LPL-mediated lipolysis, and providing higher affinity remnants for the LDL receptor (3).

A meta-analysis of 53 clinical studies using fibrates enrolling 16,802 subjects indicated that apart from a 36% reduction in plasma TG, fibrates increase HDL-cholesterol levels by ~10% in humans (5). Studies in vitro and in (transgenic) mice showed that fibrates increase the hepatic transcription of human APOA1 (6) and APOA2 (7), decrease hepatic scavenger receptor class B type I (SR-BI) protein (8), increase the SR-BI-mediated (9) and ABCA1-mediated (10) cholesterol efflux from human macrophages, and increase plasma phospholipid transfer protein (PLTP) activity (11, 12). All of these effects may thus potentially contribute to the increase in HDL-cholesterol observed in humans.

Abbreviations: apoE, apolipoprotein E; CE, cholesteryl ester; CETP, cholesteryl ester transfer protein; COEth, cholesteryl oleyl ether; E3L, APOE*3-Leiden; FCR, fractional catabolic rate; LXR, liver X receptor; PLTP, phospholipid transfer protein; PPARα, peroxisome proliferator-activated receptor α; PPRE, peroxisome proliferator response element; SR-BI, scavenger receptor class B type I; TC, total plasma cholesterol; TG, triglyceride.

[1] C. C. van der Hoogt and W. de Haan contributed equally to this study.
[2] To whom correspondence should be addressed.
  e-mail: p.c.n.rensen@lumc.nl

In contrast to humans, fibrates decrease HDL-cholesterol levels in apolipoprotein E (apoE)-deficient mice (13) and do not affect HDL-cholesterol levels but increase the HDL particle size in wild-type mice and human *APOA1* transgenic mice by downregulation of SR-BI (8) and/or induction of PLTP (11). The fact that fibrates do not increase the level of regularly sized HDLs in mice may be attributed to the fact that, in contrast to the human *APOA1* promoter, which contains a functional positive PPRE leading to increased *APOA1* transcription, the murine *apoa1* promoter contains a nonfunctional PPRE (6). However, another major difference between both species is that, in contrast to humans (14), mice do not express the cholesteryl ester transfer protein (CETP) (15). CETP is a hydrophobic plasma glycoprotein that is involved in the exchange of cholesteryl ester (CE) and TG between HDLs and apoB-containing lipoproteins (e.g., VLDL and LDL), resulting in the net transfer of CE from HDLs to apoB-containing lipoproteins (16). CETP deficiency in humans is associated with increased HDL-cholesterol levels (17), and inhibition of CETP activity by small-molecule inhibitors increases HDL-cholesterol levels (18–21). Interestingly, bezafibrate (22, 23), fenofibrate (24), and ciprofibrate (25) increase HDL-cholesterol in subjects with hyperlipidemia, with a concomitant reduction in plasma CETP activity. In the latter study, plasma apoA-I levels were not affected, which indicates that fibrates may increase HDL-cholesterol levels via apoA-I-independent mechanisms, including a potential effect of fibrates on CETP expression.

Therefore, our aim was to investigate whether the fibrate-induced increase in HDL-cholesterol depends on CETP expression. To this end, we used *APOE*3-Leiden* (*E3L*) mice that express a natural mutation of the human *APOE3* gene (i.e., tandem repeat of codons 120–126, yielding a protein of 306 amino acids) in addition to the human *APOC1* gene. Introduction of these genes results in an attenuated clearance of apoB-containing lipoproteins via the LDL receptor pathway. Therefore, these mice show moderately increased cholesterol and TG levels on a chow diet and a human-like lipoprotein profile on a cholesterol-rich diet (26, 27). *E3L* mice were cross-bred with mice expressing human *CETP* under the control of its natural flanking regions (28), resulting in *E3L.CETP* mice (29). *E3L.CETP* and *E3L* littermates were fed a cholesterol-rich (0.25%, w/w) diet with or without fenofibrate. After 2 weeks of administration, fenofibrate dose-dependently increased HDL-cholesterol in *E3L.CETP* mice but did not affect HDL levels in *E3L* mice. In addition, in *E3L.CETP* mice, fenofibrate reduced hepatic *CETP* mRNA expression as well as CE transfer activity in plasma. From these studies, we conclude that fenofibrate increases HDL-cholesterol by reducing the CETP-dependent transfer of CE from HDL to apoB-containing lipoproteins.

MATERIALS AND METHODS

Animals

Hemizygous human CETP transgenic (*CETP*) mice, expressing a human CETP minigene under the control of its natural flanking sequences (28), were purchased from the Jackson Laboratory (Bar Harbor, ME) and cross-bred with hemizygous *E3L* mice (30) at our Institutional Animal Facility to obtain *E3L* and *E3L.CETP* littermates (29). In this study, male mice were used, housed under standard conditions in conventional cages with free access to food and water. At the age of 8 weeks, mice were fed a semisynthetic cholesterol-rich diet, containing 0.25% (w/w) cholesterol and 15% (w/w) fat (Western-type diet; Hope Farms, Woerden, The Netherlands) for 3 weeks. Upon randomization according to total plasma cholesterol (TC) levels, mice received a Western-type diet without or with 0.004, 0.012, or 0.04% (w/w) fenofibrate (Sigma, St. Louis, MO). Experiments were performed after 4 h of fasting at 12:00 PM with food withdrawn at 8:00 AM, unless indicated otherwise. The institutional Ethical Committee on Animal Care and Experimentation approved all experiments.

Plasma lipid and lipoprotein analysis

Plasma was obtained via tail vein bleeding as described (31) and assayed for TC and TG using the commercially available enzymatic kits 236691 and 11488872 (Roche Molecular Biochemicals, Indianapolis, IN), respectively. The distribution of lipids over plasma lipoproteins was determined by fast-performance liquid chromatography using a Superose 6 column as described previously (31).

CE transfer activity in plasma

The transfer of newly synthesized CE in plasma was assayed by a radioisotope method as described previously (32). In short, [^{3}H]cholesterol was complexed with BSA and incubated overnight at 4°C with mouse plasma to equilibrate with plasma free cholesterol. Subsequently, the plasma samples were incubated for 3 h at 37°C. VLDL and LDL were then precipitated by the addition of sodium phosphotungstate/MgCl$_2$. Lipids were extracted from the precipitate with methanol-hexane (1:2, v/v), and [^{3}H]CE was separated from [^{3}H]cholesterol on silica columns, followed by counting of radioactivity.

Plasma apoA-I concentration

Plasma apoA-I concentrations were determined using a sandwich ELISA. Rabbit anti-mouse apoA-I polyclonal antibody (ab20453; Abcam plc, Cambridge, UK) was coated overnight onto Costar strips (Costar, Inc., New York, NY) (3 µg/ml) at 4°C and incubated with diluted mouse plasma (dilution, 1:400,000) for 90 min at 37°C. Subsequently, goat anti-mouse apoA-I antibody (600-101-196; Rockland Immunochemicals, Inc., Gilbertsville, PA; dilution, 1:3,000) was added and incubated for 90 min at 37°C. Finally, HRP-conjugated rabbit anti-goat IgG antibody (605-4313; Rockland Immunochemicals; dilution, 1:15,000) was added and incubated for 90 min at 37°C. HRP was detected by incubation with tetramethylbenzidine (Organon Teknika, Boxtel, The Netherlands) for 15 min at room temperature. Purified mouse apoA-I (A23100m; Biodesign International, Saco, ME) was used as a standard.

Radiolabeling of autologous HDL

One mouse from each experimental group was euthanized by cervical dislocation, and blood was drawn from the retro-orbital vein. Sera were collected and HDL was isolated after density ultracentrifugation in a SW 40 Ti rotor (Beckman Instruments, Geneva, Switzerland) (4°C, 40,000 rpm, overnight) (33). HDL (0.4 µmol of HDL-cholesterol) was radiolabeled by incubation (37°C, 24 h) with [^{3}H]cholesteryl oleyl ether ([^{3}H]COEth)-labeled egg yolk phosphatidylcholine vesicles (40 µCi, 0.5 mg of phospholipid) in the presence of lipoprotein-deficient serum

TABLE 1.	Primers for quantitative real-time PCR analysis	
Gene	Forward Primer (5′–3′)	Reverse Primer (5′–3′)
Abca1	CCCAGAGCAAAAAGCGACTC	GGTCATCATCACTTTGGTCCTTG
Apoa1	GGAGCTGCAAGGGAGACTGT	TGCGCAGAGAGTCTACGTGTGT
Cyp7a1	CAGGGAGATGCTCTGTGTTCA	AGGCATACATCCCTTCCGTGA
Pltp	TCAGTCTGCGCTGGAGTCTCT	AAGGCATCACTCCGATTTGC

Apoa1, apolipoprotein a1; *Cyp7a1*, cholesterol 7α-hydroxylase; *Pltp*, phospholipid transfer protein.

(1 ml) from *E3L.CETP* mice. Subsequently, HDL was reisolated after density ultracentrifugation (12°C, 40,000 rpm, 24 h).

In vivo clearance of autologous HDL

After 6 weeks of diet, mice were injected via the tail vein with a trace of autologous [^{3}H]COEth-labeled HDL (0.2 × 10^6 cpm in PBS) at 8:00 AM. At the indicated time points after injection, blood was collected to determine the plasma decay of [^{3}H]COEth by scintillation counting (Packard Instruments, Downers Grove, IL). The total plasma volumes of the mice were calculated from the equation V (ml) = 0.04706 × body weight (g), as determined from previous ^{125}I-BSA clearance studies (34). The fractional catabolic rate (FCR) was calculated as pools of HDL-CE cleared per hour from the plasma decay curves as described previously (35). Briefly, curves were fitted using GraphPad Prism software, giving the best fit for one-phase exponential decay curves, as described by the formula Y = span × exp(−k × x) + plateau. Subsequently, the FCR was calculated as span/(area under the curve). Taking into account the fact that the plasma level of HDL was altered by the expression of CETP and fenofibrate treatment, the FCR was also calculated from these data as millimolar HDL-CE cleared per hour, based on the actual level of HDL-CE in the various mouse groups.

Hepatic mRNA expression, SR-BI protein analysis, and lipid analysis

Livers were isolated after cervical dislocation. Total RNA was isolated using the NucleoSpin® RNA II kit (Macherey-Nagel, Düren, Germany) as recommended by the manufacturer. RNA expression was determined in duplicate by real-time PCR on a MyiQ Single-Color real-time PCR detection system (Bio-Rad Laboratories, Hercules, CA). Primers for *CETP* (36) and *Sr-b1* (37) have been described previously. Primers for *Abca1*, *Apoa1*, *Cyp7a1*, and *Pltp* are listed in **Table 1**. Expression levels were normalized using hypoxanthine-guanine phosphoribosyl transferase and cyclophilin as housekeeping genes (37, 38). Hepatic SR-BI protein was determined by immunoblot analysis as described previously (39). Liver lipids were determined by homogenizing liver samples in water (~10%, wet w/v) using a mini-bead beater (Biospec Products, Inc., Bartlesville, OK; 20 s, 5,000 rpm), followed by lipid extraction as described by Bligh and Dyer (40). Extracts were assayed for TC as described above. Protein was determined according to the method of Lowry et al. (41).

Statistical analysis

All data are presented as means ± SD unless indicated otherwise. Data were analyzed using the unpaired Student's *t*-test. *P* < 0.05 was considered statistically significant.

RESULTS

Fenofibrate increases HDL-cholesterol in *E3L.CETP* mice

To study the dose-dependent effect of fenofibrate on plasma lipid levels on a hyperlipidemic background,

E3L.CETP mice were fed a cholesterol-rich diet with increasing doses of fenofibrate in the diet (0, 0.004, 0.012, and 0.04%) for 2 weeks each (**Fig. 1**). Fenofibrate caused a dose-dependent decrease in plasma TG levels (to −62% at the highest dose; *P* < 0.05) (Fig. 1A) and only tended to reduce plasma cholesterol levels (to −35%; NS) (Fig. 1B). However, fenofibrate had a great impact on the distribution of cholesterol over the various lipoproteins. Whereas on a cholesterol-rich diet, most cholesterol in *E3L.CETP* mice is carried in (V)LDL, fenofibrate resulted in a dose-dependent shift of cholesterol from (V)LDL to HDL (Fig. 1C).

Subsequently, we compared the effect of fenofibrate on plasma lipid levels in *E3L.CETP* mice with those in *E3L*


Fig. 1. Dose-dependent effect of fenofibrate on plasma triglyceride (TG) and cholesterol in *APOE*3-Leiden.cholesteryl ester transfer protein* (*E3L.CETP*) mice. Mice received a Western-type diet with increasing doses of fenofibrate in the diet (0, 0.004, 0.012, and 0.04%) for 2 weeks each. At the end of the 2 week periods, plasma TG (A), plasma cholesterol (B), and the distribution of cholesterol over lipoproteins (C) were determined. Values are means ± SD (n = 7 per group). * *P* < 0.01 compared with controls.

mice by using the highest dose of fenofibrate (0.04%) (**Fig. 2**). In *E3L* mice, fenofibrate decreased plasma TG levels (−59%; $P < 0.001$) (Fig. 2A) to a similar extent as in *E3L.CETP* mice (−60%; $P < 0.01$) (Fig. 2B). In both *E3L* mice and *E3L.CETP* mice, these effects of fenofibrate on plasma TG levels were reflected by a strong reduction in VLDL-TG (data not shown). Fenofibrate also caused small trends toward lower plasma cholesterol levels in both *E3L* mice (Fig. 2C) and *E3L.CETP* mice (Fig. 2D). Fenofibrate similarly decreased (V)LDL-cholesterol in both *E3L* mice (−91%) and *E3L.CETP* mice (−93%). However, whereas fenofibrate did not affect HDL-cholesterol levels in *E3L* mice, fenofibrate increased HDL-cholesterol in *E3L.CETP* mice (+91%) (**Fig. 3**), consistent with the dose-increasing study (Fig. 1).

Fenofibrate increases the steady-state plasma HDL level without affecting net HDL-CE output in *E3L.CETP* mice

To examine the mechanism underlying the fenofibrate-induced increased HDL-cholesterol in *E3L.CETP* mice, *E3L* and *E3L.CETP* mice were injected with autologous [3H]COEth-labeled HDL and the plasma decay was determined (**Fig. 4**). The expression of CETP per second

Fig. 3. Effect of fenofibrate on the distribution of cholesterol over lipoproteins in *E3L* and *E3L.CETP* mice. *E3L* mice (A) and *E3L.CETP* mice (B) received a Western-type diet without (white circles) or with (black circles) fenofibrate. Plasmas of the various mouse groups were pooled (n = 6 per group). Lipoproteins were separated by fast-performance liquid chromatography, and fractions were analyzed for cholesterol.

appeared to accelerate the plasma decay, reflected by an increased FCR as calculated pools of HDL-CE cleared per hour (+65%; $P < 0.01$) (**Table 2**). In *E3L* mice, fenofibrate administration did not affect the clearance of HDL-CE (Fig. 4A, Table 1). In contrast, fenofibrate decreased the FCR of HDL in *E3L.CETP* mice (−27%; $P < 0.01$). However, taking into account the fact that CETP expression and fenofibrate treatment influence plasma HDL levels (Fig. 3), the FCR was also calculated as millimolar HDL-CE cleared per hour. In fact, CETP expression in *E3L* mice,


Fig. 2. Effect of fenofibrate on plasma TG and cholesterol in *E3L* and *E3L.CETP* mice. *E3L* mice (A, C) and *E3L.CETP* mice (B, D) received a Western-type diet without (white bars) or with (black bars) fenofibrate for 2 weeks, and plasma TG (A, B) and cholesterol (C, D) were determined. Values are means ± SD (n = 6 per group). ** $P < 0.01$ compared with controls.

Fig. 4. Effect of fenofibrate on the plasma clearance of HDL in *E3L* and *E3L.CETP* mice. *E3L* mice (A) and *E3L.CETP* mice (B) received a Western-type diet without (white circles) or with (black circles) fenofibrate. Mice were injected with autologous [3H]cholesteryl oleyl ether-labeled HDL, and plasma 3H activity was determined at the indicated time points. Values are means ± SD (n = 5 per group). ** $P < 0.01$ compared with controls.

TABLE 2. Effect of fenofibrate on the FCR of HDL-CE in *E3L* and *E3L.CETP* mice

FCR	Control	Fenofibrate
FCR (pools HDL-CE/h)		
E3L	0.067 ± 0.003	0.057 ± 0.004
E3L.CETP	0.111 ± 0.006	0.081 ± 0.003[a]
FCR (mM HDL-CE/h)		
E3L	0.166 ± 0.008	0.162 ± 0.011
E3L.CETP	0.142 ± 0.008	0.162 ± 0.007

CE, cholesteryl ester; *E3L, APOE*3-Leiden*; FCR, fractional catabolic rate. *E3L* and *E3L.CETP* mice were fed a Western-type diet with or without fenofibrate, and mice were injected with autologous [^{3}H]cholesteryl oleyl ether-labeled HDL. The data from Fig. 4 were used to calculate the FCR as pools of HDL-CE cleared per hour or millimolar HDL-CE cleared per hour. Values are expressed as means ± SEM relative to control mice (n = 5 mice per group).

[a] $P < 0.01$ compared with controls.

or fenofibrate feeding of either *E3L* or *E3L.CETP* mice, did not affect the amount (mM) of HDL-CE cleared per hour (Table 2). This indicates that CETP expression and fenofibrate feeding alter the steady-state plasma HDL-cholesterol level without affecting net HDL-cholesterol flux through the plasma. These data indicate that the residual CETP activity in *E3L.CETP* mice on fenofibrate is sufficient to maintain net HDL-CE output.

Fenofibrate does not differentially affect hepatic mRNA expression of genes involved in plasma HDL metabolism

Because differences in genes encoding proteins that are crucially involved in HDL metabolism may account for the increase in HDL-cholesterol in *E3L.CETP* mice upon fenofibrate treatment, we examined the effect of fenofibrate on their hepatic expression (**Fig. 5**). The expression of these genes was not substantially different in *E3L.CETP* mice compared with *E3L* mice. Fenofibrate increased *Pltp* in *E3L* (3.3-fold; $P < 0.01$) and *E3L.CETP* mice (2.7-fold;

$P < 0.05$), consistent with previously reported effects of fenofibrate (11, 12). The expression of *Abca1*, which is involved in HDL formation, was similarly decreased in *E3L* (−50%; $P < 0.05$) and *E3L.CETP* (−33%; $P < 0.05$) mice. Likewise, S*r-b1* was decreased in *E3L* (−48%; $P < 0.05$) and *E3L.CETP* (−42%; $P < 0.05$) mice to a similar extent, as reflected by similar reductions in hepatic SR-BI protein levels ($\sim$−25%) for *E3L* mice ($P = 0.06$) and *E3L.CETP* mice ($P < 0.05$) (data not shown). *Apoa1* expression was decreased in *E3L* (−49%; $P < 0.05$) and *E3L.CETP* (−41%; $P < 0.05$) mice, without substantially affecting the plasma apoA-I level ($\sim$80 mg/dl in all groups). The expression of *Cyp7a1, Pltp, Abca1, Sr-b1*, and *Apoa1* is thus similarly affected by fenofibrate in *E3L* and *E3L.CETP* mice and cannot explain the differentially increased HDL in *E3L.CETP* mice compared with *E3L* mice.

Fenofibrate decreases hepatic CETP mRNA expression and CE transfer activity in plasma

To investigate whether the effect of fenofibrate on increasing HDL-cholesterol in *E3L.CETP* mice is caused by a reduction of CETP activity, we determined the hepatic *CETP* expression and CE transfer activity in plasma (**Fig. 6**). Indeed, fenofibrate markedly decreased *CETP* expression in *E3L.CETP* mice (−72%; $P < 0.01$) (Fig. 6A). Because the liver X receptor (LXR) strongly regulates the expression of *CETP* (42), we determined whether fenofibrate feeding would decrease the cholesterol content in the liver. Indeed, fenofibrate reduced the hepatic cholesterol content in *E3L* mice (4.9 ± 2.6 vs. 9.6 ± 3.7 μg TC/mg protein) and *E3L.CETP* mice (3.6 ± 1.0 vs. 13.0 ± 3.7 μg TC/mg protein; $P < 0.05$). The fenofibrate-induced reduction in hepatic *CETP* expression was accompanied by a similar reduction in CE transfer activity in plasma of *E3L.CETP* mice (−73%; $P < 0.01$) (Fig. 6B). Therefore, the HDL-increasing effect of fenofibrate in *E3L.CETP* mice is likely to be a direct consequence of lower CETP expression.

Fig. 5. Effect of fenofibrate on hepatic mRNA expression in *E3L* and *E3L.CETP* mice. *E3L* mice (A) and *E3L.CETP* mice (B) were fed a Western-type diet without (white bars) or with (black bars) fenofibrate. Mice were euthanized, and livers were collected to determine mRNA expression. Values are expressed as means ± SEM relative to control mice (n = 4 per group). * $P < 0.05$, ** $P < 0.01$ compared with controls.

Fig. 6. Effect of fenofibrate on hepatic CETP mRNA expression and cholesteryl ester (CE) transfer activity in plasma of *E3L.CETP* mice. *E3L.CETP* mice received a Western-type diet without (white bars) or with (black bars) fenofibrate, and mice were euthanized. Livers were collected to determine CETP mRNA expression (A), and plasma was assayed for CE transfer activity (B). Values are means ± SD (n = 4–6 per group). ** $P < 0.01$ compared with controls.

DISCUSSION

In this study, we investigated whether CETP might play a role in the fenofibrate-induced increase in HDL-cholesterol. Here, we show that fenofibrate increases HDL-cholesterol in *E3L.CETP* mice, as paralleled by a reduction in hepatic *CETP* mRNA and plasma CE transfer activity, whereas fenofibrate does not increase HDL in *E3L* mice.

We showed previously that *E3L* mice are highly susceptible to dietary interventions with respect to modulating plasma lipid levels and that these mice show a human-like response to drug interventions aimed at reducing plasma levels of apoB-containing lipoproteins, including statins [atorvastatin (43) and rosuvastatin (44)] and fibrates [gemfibrozil (45)]. This is in sheer contrast with wild-type mice (6, 13) and more conventional hyperlipidemic mice, such as apoE-deficient (13, 46) or LDL receptor-deficient (47) mice, which show either an adverse response or no response to such interventions. In particular, administration of fenofibrate to wild-type (13) and apoE-deficient (13, 48) mice showed an unexpected increase in plasma TG and TC levels caused by increased levels of lipoprotein remnants, with a concomitant reduction in HDL-cholesterol. Here, we demonstrate that *E3L* mice also show a human-like response to fenofibrate with respect to decreasing TG and cholesterol in apoB-containing particles, although HDL-cholesterol was not increased after 2 weeks of intervention (Fig. 3A). We reasoned that the introduction of human CETP in these *E3L* mice, which permits CE exchange between HDL and apoB-containing lipoproteins, would result in an excellent mouse model to study the effects of fenofibrate on HDL metabolism.

Indeed, we demonstrate that although *E3L.CETP* mice retain their ability to respond to fenofibrate with respect to a similar reduction of VLDL-TG and VLDL-cholesterol compared with *E3L* mice, they also respond with an increase in HDL-cholesterol level. Apparently, the fact that mice normally do not express CETP prevents a human-like response to HDL-modulating drug interventions, such as fibrate treatment. In agreement with this hypothesis, we observed previously that treatment of *E3L* mice with statins also did not increase HDL-cholesterol, even though VLDL reductions of as much as 60% were achieved (43, 45, 49).

HDL-cholesterol levels can theoretically be modulated by several key proteins involved in HDL metabolism, including ABCA1 (10), SR-BI (9), PLTP (11, 23), apoA-I (3, 6, 48, 50, 51), and CETP (22, 24, 25). Therefore, we examined the potential contribution of each of these factors in the fenofibrate-induced increase of HDL-cholesterol in *E3L.CETP* mice. The HDL-cholesterol level in mice is largely determined by the hepatic expression of ABCA1, which plays an important role in HDL formation by mediating hepatic cholesterol efflux to apoA-I (52). In fact, it has been reported that treatment of chow-fed rats with ciprofibrate increased their hepatic *Abca1* expression, concomitant with an increase in plasma HDL-cholesterol levels (53). However, fenofibrate did not increase hepatic *Abca1* expression in either *E3L* or *E3L.CETP* mice. On the

contrary, fenofibrate decreased *Abca1* mRNA in both genotypes and thus cannot explain the selective increase of HDL-cholesterol in *E3L.CETP* mice.

Whereas bezafibrate did not increase plasma PLTP mass and activity levels in humans (23), fenofibrate has been shown to increase hepatic *Pltp* expression in mice, which was associated with increased plasma PLTP activity and HDL size, at least in human apoA-I transgenic mice (11). Accordingly, we found that fenofibrate induced the hepatic *Pltp* expression in both *E3L* and *E3L.CETP* mice. However, the relative increase was even more pronounced in *E3L* mice compared with *E3L.CETP* mice, whereas HDL-cholesterol was not affected in *E3L* mice. It is also of note that adenovirus-mediated hepatic expression of PLTP results in a dose-dependent reduction of HDL-cholesterol levels, instead of increasing HDL-cholesterol, in both wild-type and human apoA-I transgenic mice (54). It is thus unlikely that the induction of PLTP is the cause of the increase in HDL-cholesterol in *E3L.CETP* mice.

In mice, hepatic SR-BI represents the most important pathway for the selective clearance of HDL-associated CE from plasma (55). It has been shown that fenofibrate can downregulate hepatic SR-BI protein in wild-type mice, independent of *Sr-b1* expression, via a posttranscriptional mechanism. This was correlated with a substantially increased HDL size, based on fast-performance liquid chromatography profiling (8). We found that fenofibrate treatment did result in a similar reduction of *Sr-b1* expression in *E3L* mice (-48%) and *E3L.CETP* mice (-42%), with a concomitant reduction in hepatic SR-BI protein levels ($\sim-25\%$). Although fenofibrate did not increase large HDL_1 in *E3L* mice after only 2 weeks of fenofibrate intervention (Fig. 3A), cholesterol within large HDL_1 was indeed increased ($+69\%$) after prolonged treatment of *E3L* mice (i.e., 6 weeks), as has been shown for wild-type mice (8). In *E3L.CETP* mice, fenofibrate treatment for 2 weeks mainly increased the levels of cholesterol in regularly sized HDLs but also increased the levels of HDL_1 to some extent (Figs. 1C, 3B). Therefore, the reduction in hepatic SR-BI levels may contribute to the appearance of HDL_1 in both *E3L* and *E3L.CETP* mice but does not explain the increase of regularly sized HDL in *E3L.CETP* mice.

In *APOA1* transgenic mice, human apoA-I hepatic mRNA and plasma protein levels were increased after fenofibrate treatment (6), probably by the binding of PPARα to a positive PPRE in the human apoA-I gene promoter (51). Given the tight relation between HDL-cholesterol and apoA-I levels in humans, it could be expected that the upregulation of apoA-I expression would be the main causal factor for increasing HDL-cholesterol levels in humans. Fenofibrate treatment has an opposite effect on murine apoA-I (i.e., reduction of expression and plasma levels) (6), which theoretically could easily explain why fenofibrate does not increase HDL-cholesterol in mice. However, although we did observe a reduction in hepatic *apoa1* expression upon fenofibrate treatment of *E3L* (-49%) and *E3L.CETP* (-41%) mice, HDL-cholesterol was nevertheless markedly increased in

E3L.CETP mice. The fact that plasma apoA-I was not affected by fenofibrate treatment may be explained by increased lipidation of apoA-I, thereby preventing the clearance of apoA-I.

Collectively, these data suggest that downregulation of CETP expression is the predominant cause of the fenofibrate-induced increase of HDL-cholesterol. Expression of CETP in *E3L* mice decreased the HDL-cholesterol level ($\sim -35\%$) but did not affect HDL turnover, calculated as millimolar HDL-CE cleared per hour. Likewise, CETP inhibition in rabbits, although increasing HDL-cholesterol, does not compromise the HDL-CE clearance from plasma (56). Treatment of *E3L.CETP* mice with fenofibrate resulted in an increased HDL-cholesterol level, strongly decreased hepatic CETP expression levels, and reduced CE transfer activity in plasma. Thus, the increase in HDL-cholesterol may be caused by the combination of reduced hepatic *CETP* expression and reduced levels of apoB-containing lipoproteins as CE acceptors, thereby inhibiting the CETP-mediated transfer of CE from HDL to (V)LDL.

It is tempting to speculate about the mechanism(s) underlying the effect of fenofibrate on hepatic *CETP* expression. Dietary cholesterol has been shown to increase *CETP* mRNA expression in CETP transgenic mice (28, 29), presumably via an LXR-responsive element in the CETP promoter (42). Conversely, a decrease in hepatic *CETP* mRNA expression might be the consequence of a reduction in LXR signaling. Fenofibrate treatment indeed decreased hepatic cholesterol, which is likely to reduce the level of oxysterols, the natural ligands of LXRα. Downregulation of LXRα is supported by a concomitant decrease in the expression of *Cyp7a1*, another LXR target gene (57). This is in accordance with the observation that administration of ciprofibrate to wild-type mice caused a 65% reduction in hepatic *Cyp7a1* mRNA (58). Nevertheless, it should be mentioned that *Cyp7a1* is also regulated directly by fibrates via a negative PPRE in its promoter sequence (59). A reduction in LXRα might also explain the reduction of *abca1* expression (60). In addition to these mechanisms explaining reduced CETP expression by fenofibrate, a potential PPRE in the promoter region of CETP was recently identified (61), which provides the possibility for direct regulation of CETP by PPARα agonists, although it is unclear whether this potential PPRE is functional.

Our finding that fenofibrate reduced CETP activity in *E3L.CETP* mice corroborates the outcome of two human studies. Although one study failed to detect an effect of fenofibrate on plasma CETP activity (62), fenofibrate treatment did decrease CETP activity by 26% in subjects with combined hyperlipidemia (24) and by 18% in subjects with the metabolic syndrome (63). Based on our experimental study, the fenofibrate-induced decrease in CETP activity in humans is likely also a causal factor for the generally observed increase in HDL-cholesterol.

Fibrate treatment has been associated with a reduction of cardiovascular disease (5). The recent FIELD study, which assessed the effects of fenofibrate on cardiovascular risk in subjects with type 2 diabetes mellitus in a long-term, controlled trial, showed a reduction in total cardiovascular events but did not reveal a reduced risk of the primary outcome of coronary events (64). Nevertheless, the authors suggested that a more beneficial outcome might have been masked by a larger portion of statin treatment in the placebo group compared with the fenofibrate group. Even though the benefit of an increase in HDL-cholesterol by CETP inhibition is still under debate (65–68), and despite the recent failure of the CETP inhibitor torcetrapib in the ILLUMINATE study (69), increasing HDL-cholesterol levels is still generally considered antiatherogenic. Besides the ability of fibrates to potently reduce plasma TG, their concomitant effect on increasing HDL by reducing CETP expression may be an additional advantageous antiatherogenic property. We speculate that combination therapies of fibrates (i.e., reducing CETP expression) and small-molecule CETP inhibitors (i.e., reducing plasma CETP activity) may help to further reduce cardiovascular risk.

Together, our data show that fenofibrate increases HDL-cholesterol by reducing CETP expression and plasma CE transfer activity in *E3L.CETP* mice. Therefore, we postulate that reduction of CETP expression also contributes to the increase in HDL that is found in human subjects treated with fibrates. Furthermore, we anticipate that the *E3L.CETP* mouse is a valuable model in which to test the effect of combination therapies (i.e., fibrates and CETP inhibitors) on plasma lipid metabolism and atherosclerosis.

REFERENCES

1. Hokanson, J. E., and M. A. Austin. 1996. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. *J. Cardiovasc. Risk.* **3:** 213–219.
2. Chapman, M. J. 2003. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. *Atherosclerosis.* **171:** 1–13.
3. Staels, B., J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J. C. Fruchart. 1998. Mechanism of action of fibrates on lipid and lipoprotein metabolism. *Circulation.* **98:** 2088–2093.
4. Schoonjans, K., B. Staels, and J. Auwerx. 1996. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. *Biochim. Biophys. Acta.* **1302:** 93–109.
5. Birjmohun, R. S., B. A. Hutten, J. J. Kastelein, and E. S. Stroes. 2005. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. *J. Am. Coll. Cardiol.* **45:** 185–197.

6. Berthou, L., N. Duverger, F. Emmanuel, S. Langouet, J. Auwerx, A. Guillouzo, J. C. Fruchart, E. Rubin, P. Denefle, B. Staels, et al. 1996. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. *J. Clin. Invest.* **97:** 2408–2416.

7. Vu-Dac, N., K. Schoonjans, V. Kosykh, J. Dallongeville, J. C. Fruchart, B. Staels, and J. Auwerx. 1995. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. *J. Clin. Invest.* **96:** 741–750.

8. Mardones, P., A. Pilon, M. Bouly, D. Duran, T. Nishimoto, H. Arai, K. F. Kozarsky, M. Altayo, J. F. Miquel, G. Luc, et al. 2003. Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice. *J. Biol. Chem.* **278:** 7884–7890.

9. Chinetti, G., F. G. Gbaguidi, S. Griglio, Z. Mallat, M. Antonucci, P. Poulain, J. Chapman, J. C. Fruchart, A. Tedgui, J. Najib-Fruchart, et al. 2000. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. *Circulation.* **101:** 2411–2417.

10. Chinetti, G., S. Lestavel, V. Bocher, A. T. Remaley, B. Neve, I. P. Torra, E. Teissier, A. Minnich, M. Jaye, N. Duverger, et al. 2001. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. *Nat. Med.* **7:** 53–58.

11. Bouly, M., D. Masson, B. Gross, X. C. Jiang, C. Fievet, G. Castro, A. R. Tall, J. C. Fruchart, B. Staels, L. Lagrost, et al. 2001. Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. *J. Biol. Chem.* **276:** 25841–25847.

12. Lie, J., I. M. Lankhuizen, B. Gross, T. van Gent, R. van Haperen, L. Scheek, B. Staels, R. de Crom, and A. Van Tol. 2005. Fenofibrate reverses the decline in HDL cholesterol in mice overexpressing human phospholipid transfer protein. *Biochim. Biophys. Acta.* **1738:** 48–53.

13. Declercq, V., B. Yeganeh, G. R. Moshtaghi-Kashanian, H. Khademi, B. Bahadori, and M. H. Moghadasian. 2005. Paradoxical effects of fenofibrate and nicotinic acid in apo E-deficient mice. *J. Cardiovasc. Pharmacol.* **46:** 18–24.

14. Ha, Y. C., and P. J. Barter. 1982. Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. *Comp. Biochem. Physiol. B.* **71:** 265–269.

15. Jiao, S., T. G. Cole, R. T. Kitchens, B. Pfleger, and G. Schonfeld. 1990. Genetic heterogeneity of lipoproteins in inbred strains of mice: analysis by gel-permeation chromatography. *Metabolism.* **39:** 155–160.

16. Hesler, C. B., T. L. Swenson, and A. R. Tall. 1987. Purification and characterization of a human plasma cholesteryl ester transfer protein. *J. Biol. Chem.* **262:** 2275–2282.

17. Yamashita, S., D. Y. Hui, J. R. Wetterau, D. L. Sprecher, J. A. Harmony, N. Sakai, Y. Matsuzawa, and S. Tarui. 1991. Characterization of plasma lipoproteins in patients heterozygous for human plasma cholesteryl ester transfer protein (CETP) deficiency: plasma CETP regulates high-density lipoprotein concentration and composition. *Metabolism.* **40:** 756–763.

18. Brousseau, M. E., E. J. Schaefer, M. L. Wolfe, L. T. Bloedon, A. G. Digenio, R. W. Clark, J. P. Mancuso, and D. J. Rader. 2004. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. *N. Engl. J. Med.* **350:** 1505–1515.

19. Clark, R. W., T. A. Sutfin, R. B. Ruggeri, A. T. Willauer, E. D. Sugarman, G. Magnus-Aryitey, P. G. Cosgrove, T. M. Sand, R. T. Wester, J. A. Williams, et al. 2004. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. *Arterioscler. Thromb. Vasc. Biol.* **24:** 490–497.

20. de Grooth, G. J., J. A. Kuivenhoven, A. F. Stalenhoef, J. de Graaf, A. H. Zwinderman, J. L. Posma, A. Van Tol, and J. J. Kastelein. 2002. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. *Circulation.* **105:** 2159–2165.

21. Kuivenhoven, J. A., G. J. de Grooth, H. Kawamura, A. H. Klerkx, F. Wilhelm, M. D. Trip, and J. J. Kastelein. 2005. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. *Am. J. Cardiol.* **95:** 1085–1088.

22. Homma, Y., H. Ozawa, T. Kobayashi, H. Yamaguchi, H. Sakane, Y. Mikami, Y. Mikami, and H. Nakamura. 1994. Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia. *Atherosclerosis.* **106:** 191–201.

23. Jonkers, I. J., A. H. Smelt, H. Hattori, L. M. Scheek, T. van Gent, F. H. de Man, A. van der Laarse, and A. van Tol. 2003. Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy. *J. Lipid Res.* **44:** 1462–1469.

24. Guerin, M., E. Bruckert, P. J. Dolphin, G. Turpin, and M. J. Chapman. 1996. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. *Arterioscler. Thromb. Vasc. Biol.* **16:** 763–772.

25. Guerin, M., W. Le Goff, E. Frisdal, S. Schneider, D. Milosavljevic, E. Bruckert, and M. J. Chapman. 2003. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux. *J. Clin. Endocrinol. Metab.* **88:** 3738–3746.

26. van Vlijmen, B. J., A. M. van den Maagdenberg, M. J. Gijbels, H. van der Boom, H. HogenEsch, R. R. Frants, M. H. Hofker, and L. M. Havekes. 1994. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. *J. Clin. Invest.* **93:** 1403–1410.

27. van Vlijmen, B. J., R. P. Mensink, H. B. 't Hof, R. F. Offermans, M. H. Hofker, and L. M. Havekes. 1998. Effects of dietary fish oil on serum lipids and VLDL kinetics in hyperlipidemic apolipoprotein E*3-Leiden transgenic mice. *J. Lipid Res.* **39:** 1181–1188.

28. Jiang, X. C., L. B. Agellon, A. Walsh, J. L. Breslow, and A. Tall. 1992. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. *J. Clin. Invest.* **90:** 1290–1295.

29. Westerterp, M., C. C. van der Hoogt, W. de Haan, E. H. Offerman, G. M. Dallinga-Thie, J. W. Jukema, L. M. Havekes, and P. C. Rensen. 2006. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. *Arterioscler. Thromb. Vasc. Biol.* **26:** 2552–2559.

30. van den Maagdenberg, A. M., M. H. Hofker, P. J. Krimpenfort, I. de Bruijn, B. van Vlijmen, H. van der Boom, L. M. Havekes, and R. R. Frants. 1993. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. *J. Biol. Chem.* **268:** 10540–10545.

31. Berbee, J. F., C. C. van der Hoogt, D. Sundararaman, L. M. Havekes, and P. C. Rensen. 2005. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. *J. Lipid Res.* **46:** 297–306.

32. Dullaart, R. P., S. C. Riemens, L. M. Scheek, and A. Van Tol. 1999. Insulin decreases plasma cholesteryl ester transfer but not cholesterol esterification in healthy subjects as well as in normotriglyceridaemic patients with type 2 diabetes. *Eur. J. Clin. Invest.* **29:** 663–671.

33. Redgrave, T. G., D. C. Roberts, and C. E. West. 1975. Separation of plasma lipoproteins by density-gradient ultracentrifugation. *Anal. Biochem.* **65:** 42–49.

34. Jong, M. C., P. C. Rensen, V. E. Dahlmans, H. van der Boom, T. J. van Berkel, and L. M. Havekes. 2001. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. *J. Lipid Res.* **42:** 1578–1585.

35. Le, N. A., R. Ramakrishnan, R. B. Dell, H. N. Ginsberg, and W. V. Brown. 1986. Kinetic analysis using specific radioactivity data. *Methods Enzymol.* **129:** 384–395.

36. Gautier, T., D. Masson, M. C. Jong, J. P. Pais de Barros, L. Duverneuil, N. Le Guern, V. Deckert, L. Dumont, A. Bataille, Z. Zak, et al. 2005. Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice. *Biochem. J.* **385:** 189–195.

37. Out, R., M. Hoekstra, S. C. de Jager, P. de Vos, D. R. van der Westhuyzen, N. R. Webb, M. Van Eck, E. A. Biessen, and T. J. van Berkel. 2005. Adenovirus-mediated hepatic overexpression of scavenger receptor class B type I accelerates chylomicron metabolism in C57BL/6J mice. *J. Lipid Res.* **46:** 1172–1181.

38. Post, S. M., M. Groenendijk, K. Solaas, P. C. Rensen, and H. M. Princen. 2004. Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background impairs very-low-density lipoprotein production. *Arterioscler. Thromb. Vasc. Biol.* **24:** 768–774.

39. Van Eck, M., J. Twisk, M. Hoekstra, B. T. Van Rij, C. A. Van der Lans, I. S. Bos, J. K. Kruijt, F. Kuipers, and T. J. van Berkel. 2003. Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver. *J. Biol. Chem.* **278:** 23699–23705.

40. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. *Can. J. Biochem. Physiol.* **37:** 911–917.

41. Lowry, O. H., N. J. Rosenbrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* **193:** 265–275.

42. Luo, Y., and A. R. Tall. 2000. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. *J. Clin. Invest.* **105:** 513–520.

43. Delsing, D. J., J. W. Jukema, M. A. van de Wiel, J. J. Emeis, A. van der Laarse, L. M. Havekes, and H. M. Princen. 2003. Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. *J. Cardiovasc. Pharmacol.* **42:** 63–70.

44. Kleemann, R., H. M. Princen, J. J. Emeis, J. W. Jukema, R. D. Fontijn, A. J. Horrevoets, T. Kooistra, and L. M. Havekes. 2003. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. *Circulation.* **108:** 1368–1374.

45. van Vlijmen, B. J., N. J. Pearce, M. Bergo, B. Staels, J. W. Yates, A. D. Gribble, B. C. Bond, M. H. Hofker, L. M. Havekes, and P. H. Groot. 1998. Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs. *Arzneimittelforschung.* **48:** 396–402.

46. Duez, H., Y. S. Chao, M. Hernandez, G. Torpier, P. Poulain, S. Mundt, Z. Mallat, E. Teissier, C. A. Burton, A. Tedgui, et al. 2002. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. *J. Biol. Chem.* **277:** 48051–48057.

47. Fu, T., D. Mukhopadhyay, N. O. Davidson, and J. Borensztajn. 2004. The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions. *J. Biol. Chem.* **279:** 28662–28669.

48. Duez, H., B. Lefebvre, P. Poulain, I. P. Torra, F. Percevault, G. Luc, J. M. Peters, F. J. Gonzalez, R. Gineste, S. Helleboid, et al. 2005. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. *Arterioscler. Thromb. Vasc. Biol.* **25:** 585–591.

49. Delsing, D. J., S. M. Post, M. Groenendijk, K. Solaas, H. van der Boom, W. van Duyvenvoorde, E. C. de Wit, V. W. Bloks, F. Kuipers, L. M. Havekes, et al. 2005. Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-Leiden mice. *J. Cardiovasc. Pharmacol.* **45:** 53–60.

50. Mellies, M. J., E. A. Stein, P. Khoury, G. Lamkin, and C. J. Glueck. 1987. Effects of fenofibrate on lipids, lipoproteins, and apo-lipoproteins in 33 subjects with primary hypercholesterolemia. *Atherosclerosis.* **63:** 57–64.

51. Vu-Dac, N., K. Schoonjans, B. Laine, J. C. Fruchart, J. Auwerx, and B. Staels. 1994. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. *J. Biol. Chem.* **269:** 31012–31018.

52. Timmins, J. M., J. Y. Lee, E. Boudyguina, K. D. Kluckman, L. R. Brunham, A. Mulya, A. K. Gebre, J. M. Coutinho, P. L. Colvin, T. L. Smith, et al. 2005. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. *J. Clin. Invest.* **115:** 1333–1342.

53. Guan, J. Z., N. Tamasawa, H. Murakami, J. Matsui, K. Yamato, and T. Suda. 2003. Clofibrate, a peroxisome-proliferator, enhances reverse cholesterol transport through cytochrome P450 activation and oxysterol generation. *Tohoku J. Exp. Med.* **201:** 251–259.

54. Ehnholm, S., K. W. van Dijk, B. van 't Hof, A. van der Zee, V. M. Olkkonen, M. Jauhiainen, M. Hofker, L. Havekes, and C. Ehnholm. 1998. Adenovirus mediated overexpression of human phospholipid transfer protein alters plasma HDL levels in mice. *J. Lipid Res.* **39:** 1248–1253.

55. Out, R., M. Hoekstra, J. A. Spijkers, J. K. Kruijt, M. Van Eck, I. S. Bos, J. Twisk, and T. J. van Berkel. 2004. Scavenger receptor class B type I is solely responsible for the selective uptake of cholesteryl esters from HDL by the liver and the adrenals in mice. *J. Lipid Res.* **45:** 2088–2095.

56. Kee, P., D. Caiazza, K. A. Rye, P. H. Barrett, L. A. Morehouse, and P. J. Barter. 2006. Effect of inhibiting cholesteryl ester transfer protein on the kinetics of high-density lipoprotein cholesteryl ester transport in plasma: in vivo studies in rabbits. *Arterioscler. Thromb. Vasc. Biol.* **26:** 884–890.

57. Lehmann, J. M., S. A. Kliewer, L. B. Moore, T. A. Smith-Oliver, B. B. Oliver, J. L. Su, S. S. Sundseth, D. A. Winegar, D. E. Blanchard, T. A. Spencer, et al. 1997. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. *J. Biol. Chem.* **272:** 3137–3140.

58. Post, S. M., H. Duez, P. P. Gervois, B. Staels, F. Kuipers, and H. M. Princen. 2001. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. *Arterioscler. Thromb. Vasc. Biol.* **21:** 1840–1845.

59. Marrapodi, M., and J. Y. Chiang. 2000. Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. *J. Lipid Res.* **41:** 514–520.

60. Repa, J. J., G. Liang, J. Ou, Y. Bashmakov, J. M. Lobaccaro, I. Shimomura, B. Shan, M. S. Brown, J. L. Goldstein, and D. J. Mangelsdorf. 2000. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. *Genes Dev.* **14:** 2819–2830.

61. Cheema, S. K., A. Agarwal-Mawal, C. M. Murray, and S. Tucker. 2005. Lack of stimulation of cholesteryl ester transfer protein by cholesterol in the presence of a high-fat diet. *J. Lipid Res.* **46:** 2356–2366.

62. McPherson, R., G. Agnani, P. Lau, J-C. Fruchart, A. D. Edgar, and Y. L. Marcel. 1996. Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-mediated neutral lipid transfer. *Arterioscler. Thromb. Vasc. Biol.* **16:** 1340–1346.

63. Watts, G. F., J. Ji, D. C. Chan, E. M. M. Ooi, A. G. Johnson, K-A. Rye, and P. H. R. Barrett. 2006. Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome. *Clin. Sci. (Lond.).* **111:** 193–199.

64. Keech, A., R. J. Simes, P. Barter, J. Best, R. Scott, M. R. Taskinen, P. Forder, A. Pillai, T. Davis, P. Glasziou, et al. 2005. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet.* **366:** 1849–1861.

65. Hirano, K., S. Yamashita, and Y. Matsuzawa. 2000. Pros and cons of inhibiting cholesteryl ester transfer protein. *Curr. Opin. Lipidol.* **11:** 589–596.

66. Le Goff, W., M. Guerin, and M. J. Chapman. 2004. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. *Pharmacol. Ther.* **101:** 17–38.

67. Stein, O., and Y. Stein. 2005. Lipid transfer proteins (LTP) and atherosclerosis. *Atherosclerosis.* **178:** 217–230.

68. Watts, G. F. 2002. The Yin and Yang of cholesteryl ester transfer protein and atherosclerosis. *Clin. Sci. (Lond.).* **103:** 595–597.

69. Tall, A. R., L. Yvan-Charvet, and N. Wang. 2007. The failure of torcetrapib: was it the molecule or the mechanism? *Arterioscler. Thromb. Vasc. Biol.* **27:** 257–260.